Bills · S 3081
IN COMMITTEE· 119TH CONGRESS
Senate BillS 3081Drug safety, medical device, and laboratory regulationCongressional oversight
Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025
INTRO OCT 30· LAST ACTION OCT 30
READING
6MIN
COSPONSORS
1
READER REACTIONS0 TOTAL
NO VOTES YET · BE THE FIRST
- Introduced only
LEGISLATIVE PROGRESS
STEP 2 / 8Introduced
In Committee
Reported
Passed Senate
Passed House
Conference
To President
Became Law
WHAT THE BILL DOES
AI-writtenThis bill matters because it could dramatically speed up the availability of new medical treatments and devices in the United States. Currently, even if a drug or device is widely used and proven safe and effective in other developed nations, it still faces a long and expensive approval process with the U.S. FDA.
If this bill becomes law, it could mean that patients facing serious diseases or lacking effective treatments could get access to therapies sooner, potentially saving lives or improving quality of life. Without this bill, these products would continue to undergo the full, often years-long, traditional FDA review, regardless of their international track record, which some argue delays access to important innovations for American patients.
KEY PROVISIONS
5AI-extractedPROVISION 01
Establishes a new 'reciprocal marketing approval' pathway for drugs, biological products, and devices that are already lawfully marketed in certain foreign countries or the United Kingdom.
This provision creates a faster route for certain medical products to enter the U.S. market, potentially speeding up patient access to new treatments.
PROVISION 02
Requires products seeking reciprocal approval to meet specific eligibility criteria, including addressing a 'public health or unmet medical need' in the United States and having no outstanding safety concerns abroad or with the FDA.
These criteria ensure that only genuinely needed products with a proven safety record are considered for expedited approval, maintaining a level of patient protection.
PROVISION 03
Mandates that the FDA decide on reciprocal approval requests within 30 days but allows the FDA to decline approval if it determines a product is unsafe or ineffective, or to require postmarket studies.
This sets a strict timeline for FDA review while preserving the agency's ability to prioritize patient safety and gather additional data if necessary.
PROVISION 04
Allows Congress to disapprove an FDA decision to *decline* reciprocal marketing approval, effectively overturning the FDA's denial and allowing the product to enter the market.
This provision introduces direct congressional oversight over specific FDA decisions, potentially influencing which products are ultimately approved.
PROVISION 05
Requires the FDA to conduct an outreach campaign to inform manufacturers about this new approval pathway.
This ensures that eligible companies are aware of and encouraged to use the new process, maximizing the potential impact of the bill.
SPONSORSHIP
1 + 1
R· Texas
YRS IN OFFICE
13
BILLS LED
133
COSPONSOR BREAKDOWNBIPARTISAN · 0%
DEM 0 REP 1 IND 0
ACTION TIMELINE
2 EVENTSOCT 30
Introduced in Senate
OCT 30
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
BILL INFO
TypeSenate Bill
NumberS 3081
Congress119th
StatusIn Committee
IntroducedOct 30, 2025
Last actionOct 30, 2025
READER REACTIONS
OVERALL SENTIMENT
No reactions yet. Be the first to weigh in.
Discussion
Loading comments...
IN COMMITTEE· 119TH CONGRESS · HEALTH, EDUCATION, LABOR, AND PENSIONS COMMITTEE · INTRODUCED OCT 30, 2025
Senate BillS 3081Drug safety, medical device, and laboratory regulationCongressional oversight
Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025
INTRODUCED OCT 30, 2025· LAST ACTION OCT 30, 2025
PASSAGE CHANCES
—%
READING
6 min
COSPONSORS
1
COMPLEXITY
Moderate
